COMETE Project
Advanced metastatic colorectal and gastric cancers
PreclinicalCollaborative R&D project co-financed by EU FEDER funds.
Key Facts
Indication
Advanced metastatic colorectal and gastric cancers
Phase
Preclinical
Status
Collaborative R&D project co-financed by EU FEDER funds.
About Oncodesign Precision Medicine
Oncodesign Precision Medicine is a publicly traded biotech focused on developing innovative therapeutic and diagnostic solutions for resistant cancers and neurodegenerative diseases. Its core strength lies in the Nanocyclix® platform, which generates highly selective macrocyclic kinase inhibitors, enabling a pipeline with first-in-class and best-in-class potential. The company has secured strategic validation and funding from The Michael J. Fox Foundation for its Parkinson's program and is advancing multiple clinical-stage assets while exploring radiotheranostic approaches through collaborative projects like COMETE.
View full company profile